Dendreon Announces Presentation of Data at the 35th European Society for Medical Oncology Congress

SEATTLE and MILAN, October 9, 2010 - Dendreon Corporation (Nasdaq: DNDN) today announced the following data
presentations taking place at the 35th European Society for Medical Oncology
(ESMO) congress in Milan, Italy:

    - Saturday, October 9, 2010, 13:00 - 14:00 CEST - "Integrated Safety
      Results from 4 Randomized, Double-blind, Placebo-controlled Studies of
      Sipuleucel-T." Poster presentation.

    - Monday, October 11, 2010, 12:30 - 13:30 CEST - "Survival Results of the
      IMPACT Trial of Sipuleucel-T for Advanced Prostate Cancer." Poster
      discussion.

    - Monday, October 11, 2010, 12:30 - 13:30 CEST - "Results from Two Phase
      1 Trials of Her2/Neu Directed Active Cellular Immunotherapy in Patients
      Advanced Malignancies." Poster discussion.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company
applies its expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy product candidates
designed to stimulate an immune response in a variety of tumor types.
Dendreon's first product, sipuleucel-T (marketed in the U.S. as PROVENGE(R)),
was approved by the U.S. Food and Drug Administration (FDA) in April 2010.
Dendreon is exploring the application of additional ACI product candidates
and small molecules for the potential treatment of a variety of cancers. The
Company is headquartered in Seattle, Washington and is traded on the NASDAQ
Global Market under the symbol DNDN. For more information about the Company
and its programs, visit www.dendreon.com/.

Katherine Stueland, Vice President, Corporate Communications and Investor Relations, +1-206-829-1522, kstueland at dendreon.com